Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.56 |
| ▸ | CFTR | P13569 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8556728 | 0.86 | ALDH1A1 (0.49) | KDM4EALDH1A1HSD17B10CFTRLMNA | |
| SCHEMBL16401931 | 0.85 | HSD17B10 (0.60) | KDM4EALDH1A1HSD17B10LMNATSHR | |
| SCHEMBL10710427 | 0.85 | ALDH1A1 (0.48) | KDM4EALDH1A1HSD17B10CFTRLMNA | |
| SCHEMBL7957850 | 0.84 | ALDH1A1 (0.70) | KDM4EALDH1A1HSD17B10CFTRLMNA | |
| SCHEMBL2430731 | 0.83 | LMNA (0.54) | KDM4EALDH1A1HSD17B10CFTRLMNA | |
| SCHEMBL2422146 | 0.82 | KDM4E (0.48) | KDM4EALDH1A1HSD17B10LMNAHTT | |
| SCHEMBL461024 | 0.81 | MMP2 (0.50) | KDM4EALDH1A1HSD17B10TSHRGAA | |
| SCHEMBL9419211 | 0.81 | ALDH1A1 (0.45) | KDM4EALDH1A1HSD17B10TSHRGAA | |
| SCHEMBL5929896 | 0.81 | ALDH1A1 (0.62) | KDM4EALDH1A1HSD17B10CFTRLMNA | |
| SCHEMBL25362705 | 0.80 | ALDH1A1 (0.61) | KDM4EALDH1A1HSD17B10CFTRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160122342-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-05 | — | — | US | disclosed |
| US-20160122342-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-05 | — | — | US | disclosed |
| US-20160122342-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-05 | — | — | US | disclosed |
| EP-3004096-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014195919-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014195919-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122342-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | KDM4E 55/4885ALDH1A1 2517/4885HSD17B10 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.